<?xml version="1.0" encoding="utf-8"?>
<journal>
<title>International Journal of Radiation Research</title>
<title_fa>نشریه پرتو پژوه</title_fa>
<short_title>Int J Radiat Res</short_title>
<subject>Basic Sciences</subject>
<web_url>http://ijrr.com</web_url>
<journal_hbi_system_id>79</journal_hbi_system_id>
<journal_hbi_system_user>journal79</journal_hbi_system_user>
<journal_id_issn>2322-3243</journal_id_issn>
<journal_id_issn_online>2345-4229</journal_id_issn_online>
<journal_id_pii></journal_id_pii>
<journal_id_doi>10.61882/ijrr</journal_id_doi>
<journal_id_iranmedex></journal_id_iranmedex>
<journal_id_magiran></journal_id_magiran>
<journal_id_sid></journal_id_sid>
<journal_id_nlai></journal_id_nlai>
<journal_id_science></journal_id_science>
<language>en</language>
<pubdate>
	<type>jalali</type>
	<year>1403</year>
	<month>10</month>
	<day>1</day>
</pubdate>
<pubdate>
	<type>gregorian</type>
	<year>2025</year>
	<month>1</month>
	<day>1</day>
</pubdate>
<volume>23</volume>
<number>1</number>
<publish_type>online</publish_type>
<publish_edition>1</publish_edition>
<article_type>fulltext</article_type>
<articleset>
	<article>


	<language>en</language>
	<article_id_doi></article_id_doi>
	<title_fa></title_fa>
	<title>MicroRNA-18a-5p targets Sec61 translocon alpha 1 subunit to repress hepatocellular carcinoma cell growth before chromradiotherapy</title>
	<subject_fa>Radiation Biology</subject_fa>
	<subject>Radiation Biology</subject>
	<content_type_fa>تحقيق بديع</content_type_fa>
	<content_type>Original Research</content_type>
	<abstract_fa></abstract_fa>
	<abstract>&lt;div style=&quot;text-align: justify;&quot;&gt;&lt;span style=&quot;font-size:10pt&quot;&gt;&lt;span style=&quot;text-justify:newspaper&quot;&gt;&lt;span style=&quot;text-kashida-space:50%&quot;&gt;&lt;span style=&quot;line-height:119%&quot;&gt;&lt;span style=&quot;font-family:Calibri&quot;&gt;&lt;span style=&quot;color:black&quot;&gt;&lt;span lang=&quot;en-US&quot; style=&quot;font-size:9.0pt&quot;&gt;&lt;span style=&quot;font-family:Calibri&quot;&gt;&lt;span style=&quot;color:#1f497d&quot;&gt;&lt;span style=&quot;font-style:italic&quot;&gt;&lt;span style=&quot;font-weight:bold&quot;&gt;&lt;span style=&quot;language:en-US&quot;&gt;Background&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span lang=&quot;en-US&quot; style=&quot;font-size:9.0pt&quot;&gt;&lt;span style=&quot;font-family:Calibri&quot;&gt;&lt;span style=&quot;color:#1f497d&quot;&gt;&lt;span style=&quot;font-weight:bold&quot;&gt;&lt;span style=&quot;language:en-US&quot;&gt;:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt; &lt;span lang=&quot;en-GB&quot; style=&quot;font-size:9.0pt&quot;&gt;&lt;span style=&quot;font-family:Calibri&quot;&gt;&lt;span style=&quot;color:black&quot;&gt;&lt;span style=&quot;language:en-GB&quot;&gt;Hepatocellular carcinoma (HCC) cell development was investigated in relation to the regulation of Sec61 translocon alpha 1 subunit (SEC61A1) by microRNA (miR)-18a-5p. &lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span lang=&quot;en-GB&quot; style=&quot;font-size:9.0pt&quot;&gt;&lt;span style=&quot;font-family:Calibri&quot;&gt;&lt;span style=&quot;color:#1f497d&quot;&gt;&lt;span style=&quot;font-style:italic&quot;&gt;&lt;span style=&quot;font-weight:bold&quot;&gt;&lt;span style=&quot;language:en-GB&quot;&gt;Materials and Methods: &lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span lang=&quot;en-GB&quot; style=&quot;font-size:9.0pt&quot;&gt;&lt;span style=&quot;font-family:Calibri&quot;&gt;&lt;span style=&quot;color:black&quot;&gt;&lt;span style=&quot;language:en-GB&quot;&gt;After collection of clinical samples, the transfection of interfering vectors of miR-18a-5p or SEC61A1 was into HCC cells to figure out their roles in development of HCC. The Pearson test and starBase analyzed the association and target prediction of miR-18a-5p. Subsequently, through the dual luciferase reporter experiment, SEC61A1 can be regulated via miR-18a-5p. The salvage experiment revealed that miR-18a-5p influence the degradation process of Hepatocellular carcinoma through combining SEC61A1. &lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span lang=&quot;en-GB&quot; style=&quot;font-size:9.0pt&quot;&gt;&lt;span style=&quot;font-family:Calibri&quot;&gt;&lt;span style=&quot;color:#1f497d&quot;&gt;&lt;span style=&quot;font-style:italic&quot;&gt;&lt;span style=&quot;font-weight:bold&quot;&gt;&lt;span style=&quot;language:en-GB&quot;&gt;Results: &lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span lang=&quot;en-GB&quot; style=&quot;font-size:9.0pt&quot;&gt;&lt;span style=&quot;font-family:Calibri&quot;&gt;&lt;span style=&quot;color:black&quot;&gt;&lt;span style=&quot;language:en-GB&quot;&gt;In HCC cells, we found that SEC61A1 was elevated and miR-18a-5p was downregulated. HCC cells deteriorating was considerably slowed down by the enhanced miR-18a-5p level. The outcomes demonstrated that miR-18a-5p can interact and regulate SEC61A1. Additionally, the effects of earlier therapy on HCC cell proliferation can be restored by overexpressing SEC61A1. &lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span lang=&quot;en-GB&quot; style=&quot;font-size:9.0pt&quot;&gt;&lt;span style=&quot;font-family:Calibri&quot;&gt;&lt;span style=&quot;color:#1f497d&quot;&gt;&lt;span style=&quot;font-style:italic&quot;&gt;&lt;span style=&quot;font-weight:bold&quot;&gt;&lt;span style=&quot;language:en-GB&quot;&gt;Conclusion: &lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span lang=&quot;en-GB&quot; style=&quot;font-size:9.0pt&quot;&gt;&lt;span style=&quot;font-family:Calibri&quot;&gt;&lt;span style=&quot;color:black&quot;&gt;&lt;span style=&quot;language:en-GB&quot;&gt;Overall, in HCC cells and tissues miR-18a-5p was significantly downregulated, and inhibited the proliferative ability of HCC cells by targeting SEC61A1.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;</abstract>
	<keyword_fa></keyword_fa>
	<keyword>MicroRNA-18a-5p, Sec61 translocon alpha 1 subunit, hepatocellular carcinoma.</keyword>
	<start_page>175</start_page>
	<end_page>183</end_page>
	<web_url>http://ijrr.com/browse.php?a_code=A-10-1-1308&amp;slc_lang=en&amp;sid=1</web_url>


<author_list>
	<author>
	<first_name>Q. </first_name>
	<middle_name></middle_name>
	<last_name>Chen</last_name>
	<suffix></suffix>
	<first_name_fa></first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa></last_name_fa>
	<suffix_fa></suffix_fa>
	<email></email>
	<code>7900319475328460029599</code>
	<orcid>7900319475328460029599</orcid>
	<coreauthor>No</coreauthor>
	<affiliation>Department of Infectious Diseases, Ningbo Yinzhou No.2 Hospital, Yinzhou City, Ningbo, China</affiliation>
	<affiliation_fa></affiliation_fa>
	 </author>


	<author>
	<first_name>M.M. </first_name>
	<middle_name></middle_name>
	<last_name>Wang</last_name>
	<suffix></suffix>
	<first_name_fa></first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa></last_name_fa>
	<suffix_fa></suffix_fa>
	<email></email>
	<code>7900319475328460029600</code>
	<orcid>7900319475328460029600</orcid>
	<coreauthor>No</coreauthor>
	<affiliation>Department of Clinical Laboratory, The Second People’s Hospital of Nantong, Nantong City, Jiangsu, China</affiliation>
	<affiliation_fa></affiliation_fa>
	 </author>


	<author>
	<first_name>X-K. </first_name>
	<middle_name></middle_name>
	<last_name>Meng</last_name>
	<suffix></suffix>
	<first_name_fa></first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa></last_name_fa>
	<suffix_fa></suffix_fa>
	<email></email>
	<code>7900319475328460029601</code>
	<orcid>7900319475328460029601</orcid>
	<coreauthor>No</coreauthor>
	<affiliation>Department of Digestive Surgery Ward 2, Xi'an International Medical Center Hospital, Xi'an City, Shaanxi, China</affiliation>
	<affiliation_fa></affiliation_fa>
	 </author>


	<author>
	<first_name>Q.L. </first_name>
	<middle_name></middle_name>
	<last_name>Wu</last_name>
	<suffix></suffix>
	<first_name_fa></first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa></last_name_fa>
	<suffix_fa></suffix_fa>
	<email>wuquanlin123@hotmail.com </email>
	<code>7900319475328460029602</code>
	<orcid>7900319475328460029602</orcid>
	<coreauthor>No</coreauthor>
	<affiliation>Department of Digestive Surgery Ward 2, Xi'an International Medical Center Hospital, Xi'an City, Shaanxi, China</affiliation>
	<affiliation_fa></affiliation_fa>
	 </author>


</author_list>


	</article>
</articleset>
</journal>
